Vor Biopharma (VOR) 10-Q 9 May 24 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 09, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Registrant Name	VOR BIOPHARMA INC.
Entity Central Index Key	0001817229
Entity File Number	001-39979
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1591163
Entity Address, Address Line One	100 Cambridgepark Drive
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02140
City Area Code	617
Local Phone Number	655-6580
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		68,259,602
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	VOR
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 44,964	$ 31,360
Marketable securities	62,515	105,815
Prepaid expenses	3,831	3,153
Other current assets	507	475
Total current assets	111,817	140,803
Restricted cash equivalents	2,413	2,413
Property and equipment, net	9,165	10,050
Operating lease right-of-use assets	38,816	40,048
Other assets	4,819	4,812
Total assets	167,030	198,126
Current liabilities:
Accounts payable	2,325	815
Accrued liabilities	6,797	10,877
Operating lease liabilities	3,957	3,830
Other current liabilities	134	50
Total current liabilities	13,213	15,572
Long-term liabilities:
Operating lease liabilities—non-current	30,782	31,830
Total liabilities	43,995	47,402
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 68,223,496 and 67,901,610 shares issued and 68,215,771 and 67,891,311 outstanding as of March 31, 2024 and December 31, 2023, respectively	7	7
Additional paid-in capital	493,999	490,874
Accumulated other comprehensive loss	(87)	(77)
Accumulated deficit	(370,884)	(340,080)
Total stockholders' equity	123,035	150,724
Total liabilities and stockholders' equity	$ 167,030	$ 198,126

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	68,223,496	67,901,610
Common stock, shares outstanding	68,215,771	67,891,311

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 24,322	$ 21,915
General and administrative	8,004	8,507
Total operating expenses	32,326	30,422
Loss from operations	(32,326)	(30,422)
Other income:
Interest income	1,522	1,989
Total other income	1,522	1,989
Net loss	$ (30,804)	$ (28,433)
Net loss per share attributable to common stockholders, basic	$ (0.45)	$ (0.43)
Net loss per share attributable to common stockholders, diluted	$ (0.45)	$ (0.43)
Weighted-average common shares outstanding, basic	68,030,966	66,265,703
Weighted-average common shares outstanding, diluted	68,030,966	66,265,703
Other comprehensive income (loss):
Unrealized (loss) gain on available for sale marketable securities	$ (10)	$ 596
Total other comprehensive (loss) income	(10)	596
Comprehensive loss	$ (30,814)	$ (27,837)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance at Dec. 31, 2022	$ 250,607	$ 7	$ 473,587	$ (770)	$ (222,217)
Beginning Balance, Shares at Dec. 31, 2022		65,996,138
Issuance of common stock upon vesting of RSUs and exercise of stock options, net of shares withheld for taxes	(340)		(340)
Issuance of common stock upon vesting of RSUs and exercise of stock options, net of shares withheld for taxes, Shares		205,485
Issuance of common stock from open market sales agreeement	3,717		3,717
Issuance of common stock from open market sales agreeement, Shares		733,274
Stock-based compensation expense	4,068		4,068
Other comprehensive income (loss)	596			596
Net loss	(28,433)				(28,433)
Ending Balance at Mar. 31, 2023	230,215	$ 7	481,032	(174)	(250,650)
Ending Balance, Shares at Mar. 31, 2023		66,934,897
Beginning Balance at Dec. 31, 2023	$ 150,724	$ 7	490,874	(77)	(340,080)
Beginning Balance, Shares at Dec. 31, 2023	67,891,311	67,891,311
Issuance of common stock upon vesting of RSUs and exercise of stock options, net of shares withheld for taxes	$ (169)		(169)
Issuance of common stock upon vesting of RSUs and exercise of stock options, net of shares withheld for taxes, Shares		184,998
Issuance of common stock from open market sales agreeement	213		213
Issuance of common stock from open market sales agreeement, Shares		139,462
Stock-based compensation expense	3,081		3,081
Other comprehensive income (loss)	(10)			(10)
Net loss	(30,804)				(30,804)
Ending Balance at Mar. 31, 2024	$ 123,035	$ 7	$ 493,999	$ (87)	$ (370,884)
Ending Balance, Shares at Mar. 31, 2024	68,215,771	68,215,771

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (30,804)	$ (28,433)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation expense	943	837
Non-cash lease expense	1,232	1,139
Stock-based compensation	3,081	4,068
Interest amortization on marketable securities	(797)	(1,202)
Changes in operating assets and liabilities:
Operating lease liabilities	(921)	(730)
Prepaid expenses and other current assets	(710)	7
Accounts payable and accrued liabilities	(2,482)	(88)
Other assets	(7)	134
Net cash used in operating activities	(30,465)	(24,268)
Cash flow from investing activities
Purchases of marketable securities	(9,913)	(23,408)
Proceeds from maturities of marketable securities	54,000	30,000
Purchases of property and equipment	(114)	(94)
Net cash provided by investing activities	43,973	6,498
Cash flow from financing activities
Payment of issuance costs related to underwritten public offering and concurrent private placement		(717)
Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs	278	3,622
Shares repurchased for tax withholdings upon vesting of restricted stock unit awards	(182)	(400)
Proceeds from stock option exercises		14
Net cash provided by financing activities	96	2,519
Net decrease in cash, cash equivalents and restricted cash equivalents	13,604	(15,251)
Cash, cash equivalents and restricted cash equivalents, beginning of period	33,773	60,119
Cash, cash equivalents and restricted cash equivalents, end of period	47,377	44,868
Supplemental disclosure of non-cash activities
Right-of-use assets obtained in exchange for lease obligations		270
Purchases of property and equipment in accounts payable and accrued liabilities	14	$ 3
Financing costs associated with the sale of common stock included in accounts payable and accrued expenses	$ 92

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 44,964	$ 31,360	$ 42,455
Restricted cash equivalents	2,413	2,413	2,413
Total cash, cash equivalents and restricted cash equivalents as shown on the statements of cash flows	$ 47,377	$ 33,773	$ 44,868	$ 60,119

Nature of the Business

Nature of the Business	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Nature of the Business	1. Nature of the Business Vor Biopharma Inc. (the “Company”) is a clinical-stage cell and genome engineering company that combines a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. The Company’s proprietary platform leverages its expertise in hematopoietic stem cell (“HSC”) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company is headquartered in Cambridge, Massachusetts. The Company was incorporated on December 30, 2015 . Risks and Uncertainties The Company is subject to a number of risks common to development stage companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, adverse macroeconomic conditions and the need to obtain additional financing. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. As a result, the Company's continued operations are dependent on its ability to raise additional funding. The Company believes that its existing cash, cash equivalents and marketable securities at March 31, 2024 will be sufficient to allow the Company to fund its current operations through at least a period of one year after the date the financial statements are issued. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Certain comparative amounts have been reclassified to conform to the current period presentation, including the presentation of non-cash lease expense in the condensed consolidated statements of cash flows. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the condensed consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: accrued expenses and research and development expenses. Unaudited Interim Financial Information The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. The accompanying condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2023. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”). During the three months ended March 31, 2024, there have been no changes to the Company’s significant accounting policies as described in the 2023 Annual Report.

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	3. Marketable Securities The amortized cost and estimated fair value of marketable securities, by contractual maturity, are as follows: March 31, 2024 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less U.S. Treasury Bill $ 8,924 $ — $ ( 1 ) $ 8,923 U.S. Treasuries 43,758 — ( 35 ) 43,723 Maturing after one year through five years U.S. Treasuries 9,920 — ( 51 ) 9,869 Total $ 62,602 $ — $ ( 87 ) $ 62,515 December 31, 2023 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less U.S. Treasury Bill $ 8,806 $ 6 $ — $ 8,812 U.S. Treasuries 97,086 12 ( 95 ) 97,003 Total $ 105,892 $ 18 $ ( 95 ) $ 105,815 The following tables summarize the fair value and gross unrealized losses aggregated by category and the length of time that individual securities have been in an unrealized loss position: March 31, 2024 Less than twelve months Greater than twelve months Total (in thousands) Fair value Unrealized loss Fair value Unrealized loss Fair value Unrealized loss U.S. Treasury Bill $ 8,923 $ ( 1 ) $ — $ — $ 8,923 $ ( 1 ) U.S. Treasuries 26,762 ( 53 ) 26,830 ( 33 ) 53,592 ( 86 ) Total $ 35,685 $ ( 54 ) $ 26,830 $ ( 33 ) $ 62,515 $ ( 87 ) December 31, 2023 Less than twelve months Greater than twelve months Total (in thousands) Fair value Unrealized loss Fair value Unrealized loss Fair value Unrealized loss U.S. Treasuries $ — $ — $ 53,447 $ ( 95 ) $ 53,447 $ ( 95 ) Total $ — $ — $ 53,447 $ ( 95 ) $ 53,447 $ ( 95 ) The Company holds investment grade marketable securities considered to be in an unrealized loss position. Although these marketable securities are held at an unrealized loss position at March 31, 2024, the Company does not intend to sell the marketable securities prior to the value of the securities being recovered, and the Company has concluded that it is more likely than not that the marketable securities cost basis values will be recovered prior to sale of the securities and that there are no conditions or events that might require the Company to sell the securities before recovery of the cost basis occurs. Further, the Company did no t record any impairments to marketable securities or reserves for credit losses related to its marketable debt securities during the periods presented.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: March 31, 2024 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 44,868 $ — $ — $ 44,868 Marketable securities U.S. Treasury Bill 8,923 — — 8,923 U.S. Treasuries — 53,592 — 53,592 Total marketable securities 8,923 53,592 — 62,515 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 56,204 $ 53,592 $ — $ 109,796 December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 31,164 $ — $ — $ 31,164 Marketable securities U.S. Treasury Bill 8,812 — — 8,812 U.S. Treasuries — 97,003 — 97,003 Total marketable securities 8,812 97,003 — 105,815 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 42,389 $ 97,003 $ — $ 139,392 The fair value of the Company’s cash equivalents and restricted cash equivalents is based on quoted market prices in active markets with no valuation adjustment. The fair value of marketable securities was determined based o n observable market inputs. There were no transfers between levels during the three months ended March 31, 2024. Prepaid expenses, accounts payable and accrued expenses are stated at their respective historical carrying values, which approximate fair value due to their short-term nature.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net consisted of the following: March 31, December 31, (in thousands) 2024 2023 Laboratory equipment $ 10,090 $ 10,028 Manufacturing equipment 7,028 6,936 Computer equipment 432 432 Furniture, fixtures and other 620 599 Construction in progress 29 146 Total 18,199 18,141 Less: Accumulated depreciation ( 9,034 ) ( 8,091 ) Property and equipment, net $ 9,165 $ 10,050 Depreciation expense for the three months ended March 31, 2024 and 2023 was $ 0.9 million and $ 0.8 million, respectively.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Liabilities	6. Accrued Liabilities Accrued liabilities consisted of the following: March 31, December 31, (in thousands) 2024 2023 Employee-related expenses $ 1,908 $ 5,962 Professional fees 1,192 1,245 Clinical expenses 1,748 1,495 Manufacturing expenses 1,138 842 Research and development expenses 592 1,059 Other 219 274 Total accrued liabilities $ 6,797 $ 10,877

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation 2023 Inducement Plan As of March 31, 2024, the Company had 3,127,811 shares of its common stock available for future issuance under the 2023 Inducement Plan. 2021 Equity Incentive Plan As of March 31, 2024, the Company had 1,845,382 shares of its common stock available for future issuance under its 2021 Equity Incentive Plan. Stock Options The Company’s stock options generally vest over 48 months with 25 % vesting after one year followed by ratable monthly vesting over the remaining three years and have a contractual term of 10 years. The weighted-average assumptions used principally in determining the fair value of options granted were as follows: Three Months Ended March 31, 2024 2023 Expected term (in years) 6.0 6.0 Expected volatility 90.8 % 82.1 % Risk-free interest rate 4.0 % 3.8 % Dividend yield — — During the three months ended March 31, 2024 and 2023, the Company granted stock options to purchase 1,449,975 shares and 1,543,219 shares of its common stock, respectively, with a weighted-average grant-date fair value of $ 1.84 and $ 3.98 per share, respectively. As of March 31, 2024, total unrecognized compensation expense related to stock options was $ 14.0 million , which is expected to be recognized over a weighted-average period of 2.6 years. As of March 31, 2024, options for 7,725 shares of Company common stock with a weighted-average exercise price of $ 4.90 were exercised and unvested. The underlying proceeds from the unvested exercises of less than $ 0.1 million is recorded in other current liabilities on the condensed consolidated balance sheet. Restricted Stock Units During the three months ended March 31, 2024 and 2023, the Company granted 1,070,025 restricted stock units and 645,360 restricted stock units, respectively, with a weighted-average grant date fair value of $ 2.41 and $ 5.55 per share, respectively. As of March 31, 2024, total unrecognized compensation expense related to restricted stock units was $ 6.0 million , which is expected to be recognized over a weighted-average period of 2.2 years. Employee Stock Purchase Plan As of March 31, 2024, the Company had 1,968,620 shares of its common stock available for issuance under its Employee Stock Purchase Plan (“ESPP”). The Company did no t issue any shares of common stock under the ESPP during the three months ended March 31, 2024 and 2023. Stock-Based Compensation Stock-based compensation expense was allocated as follows: Three Months Ended March 31, (in thousands) 2024 2023 Research and development $ 1,405 $ 2,354 General and administrative 1,676 1,714 Total stock-based compensation expense $ 3,081 $ 4,068

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	8. Leases Cambridgepark Lease Amendments On June 15, 2021, the Company entered into the first lease amendment (“First Lease Amendment”) and second lease amendment (“Second Lease Amendment” and, together with the First Lease Amendment, the “Lease Amendments”) with PPF Off 100 Cambridge Park Drive, LLC (the “Landlord”). The Lease Amendments amended the Company’s lease agreement for its corporate office and laboratory facilities with the Landlord in Cambridge, Massachusetts to add additional leased space in the same building (the “Amended Cambridgepark Lease”). The First Lease Amendment and Second Lease Amendment commenc ed for accounting purposes on January 28, 2022 and April 29, 2022 , respectively. The terms of the Lease Amendments are through September 2030 for approximately $ 8.4 million and $ 22.3 million in fixed payments for the First Lease Amendment and Second Lease Amendment, respectively. There are no options to extend the Lease Amendments. Payments due associated with the Lease Amendments include fixed and variable payments. Variable payments relate to the Company’s share of the Landlord’s operating costs associated with the underlying assets and are recognized when the event on which those payments are assessed occurs. The Amended Cambridgepark Lease does not contain a residual value guarantee. The Lease Amendments term end dates are coterminous with the existing lease agreement. In conjunction with the Lease Amendments, the Company was required to increase its irrevocable standby letter of credit to $ 2.4 million for the benefit of the Landlord, which has been secured by money market investments and is presented as restricted cash equivalents. For further information regarding the Company’s Cambridgepark lease, please see Note 9 to the consolidated financial statements included in the 2023 Annual Report. The elements of lease expense were as follows: Three Months Ended March 31, (in thousands) 2024 2023 Operating lease cost $ 1,951 $ 1,953 Variable lease cost 530 597 Total lease cost $ 2,481 $ 2,550 Amounts reported in the condensed consolidated balance sheets and the weighted-average lease term and discount rate information were as follows: (in thousands except weighted-average amounts) March 31, 2024 December 31, 2023 Assets Operating lease right-of-use assets $ 38,816 $ 40,048 Liabilities Operating lease liabilities, current $ 3,957 $ 3,830 Operating lease liabilities, non-current 30,782 31,830 Total lease liabilities $ 34,739 $ 35,660 Weighted-Average Lease Term and Discount Rate Weighted-average remaining lease term (years) 6.5 6.7 Weighted-average discount rate 8.2 % 8.2 % The following table represents other lease activity: Three Months Ended March 31, (in thousands) 2024 2023 Other Information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 1,639 $ 1,544 Right-of-use assets obtained in exchange for lease obligations $ — $ 270

Significant Agreements

Significant Agreements	3 Months Ended
	Mar. 31, 2024
Significant Agreements [Abstract]
Significant Agreements	9. Significant Agreements Since December 31, 2023, there have been no material changes to the key terms of the Company’s license agreements. For further information regarding the Company’s existing license agreements, please see Note 10 to the consolidated financial statements included in the 2023 Annual Report.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The following table sets forth the computation of the Company’s basic and diluted net loss per share for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, (in thousands, except share and per share amounts) 2024 2023 Numerator: Net loss attributable to common stockholders $ ( 30,804 ) $ ( 28,433 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 68,030,966 66,265,703 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.45 ) $ ( 0.43 ) The Company’s potentially dilutive securities were stock options, unvested restricted stock and restricted stock units. Based on the amounts outstanding as of March 31, 2024 and 2023, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: As of March 31, 2024 2023 Options to purchase common stock 9,617,839 7,872,497 Unvested restricted stock 7,725 56,162 Restricted stock units 1,870,070 1,792,185

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Certain comparative amounts have been reclassified to conform to the current period presentation, including the presentation of non-cash lease expense in the condensed consolidated statements of cash flows. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”).
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the condensed consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: accrued expenses and research and development expenses.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. The accompanying condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2023. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”). During the three months ended March 31, 2024, there have been no changes to the Company’s significant accounting policies as described in the 2023 Annual Report.

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost and Estimated Fair Value of Marketable Securities by Contractual Maturity	The amortized cost and estimated fair value of marketable securities, by contractual maturity, are as follows: March 31, 2024 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less U.S. Treasury Bill $ 8,924 $ — $ ( 1 ) $ 8,923 U.S. Treasuries 43,758 — ( 35 ) 43,723 Maturing after one year through five years U.S. Treasuries 9,920 — ( 51 ) 9,869 Total $ 62,602 $ — $ ( 87 ) $ 62,515 December 31, 2023 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less U.S. Treasury Bill $ 8,806 $ 6 $ — $ 8,812 U.S. Treasuries 97,086 12 ( 95 ) 97,003 Total $ 105,892 $ 18 $ ( 95 ) $ 105,815
Summary of Fair Value and Gross Unrealized Losses of Marketable Securities	The following tables summarize the fair value and gross unrealized losses aggregated by category and the length of time that individual securities have been in an unrealized loss position: March 31, 2024 Less than twelve months Greater than twelve months Total (in thousands) Fair value Unrealized loss Fair value Unrealized loss Fair value Unrealized loss U.S. Treasury Bill $ 8,923 $ ( 1 ) $ — $ — $ 8,923 $ ( 1 ) U.S. Treasuries 26,762 ( 53 ) 26,830 ( 33 ) 53,592 ( 86 ) Total $ 35,685 $ ( 54 ) $ 26,830 $ ( 33 ) $ 62,515 $ ( 87 ) December 31, 2023 Less than twelve months Greater than twelve months Total (in thousands) Fair value Unrealized loss Fair value Unrealized loss Fair value Unrealized loss U.S. Treasuries $ — $ — $ 53,447 $ ( 95 ) $ 53,447 $ ( 95 ) Total $ — $ — $ 53,447 $ ( 95 ) $ 53,447 $ ( 95 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: March 31, 2024 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 44,868 $ — $ — $ 44,868 Marketable securities U.S. Treasury Bill 8,923 — — 8,923 U.S. Treasuries — 53,592 — 53,592 Total marketable securities 8,923 53,592 — 62,515 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 56,204 $ 53,592 $ — $ 109,796 December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 31,164 $ — $ — $ 31,164 Marketable securities U.S. Treasury Bill 8,812 — — 8,812 U.S. Treasuries — 97,003 — 97,003 Total marketable securities 8,812 97,003 — 105,815 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 42,389 $ 97,003 $ — $ 139,392

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: March 31, December 31, (in thousands) 2024 2023 Laboratory equipment $ 10,090 $ 10,028 Manufacturing equipment 7,028 6,936 Computer equipment 432 432 Furniture, fixtures and other 620 599 Construction in progress 29 146 Total 18,199 18,141 Less: Accumulated depreciation ( 9,034 ) ( 8,091 ) Property and equipment, net $ 9,165 $ 10,050

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following: March 31, December 31, (in thousands) 2024 2023 Employee-related expenses $ 1,908 $ 5,962 Professional fees 1,192 1,245 Clinical expenses 1,748 1,495 Manufacturing expenses 1,138 842 Research and development expenses 592 1,059 Other 219 274 Total accrued liabilities $ 6,797 $ 10,877

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Weighted-Average Assumptions Used Principally in Determining Fair Value of Options Granted	The weighted-average assumptions used principally in determining the fair value of options granted were as follows: Three Months Ended March 31, 2024 2023 Expected term (in years) 6.0 6.0 Expected volatility 90.8 % 82.1 % Risk-free interest rate 4.0 % 3.8 % Dividend yield — —
Summary of Stock-Based Compensation Expense	Stock-based compensation expense was allocated as follows: Three Months Ended March 31, (in thousands) 2024 2023 Research and development $ 1,405 $ 2,354 General and administrative 1,676 1,714 Total stock-based compensation expense $ 3,081 $ 4,068

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Summary of Lease Expense	The elements of lease expense were as follows: Three Months Ended March 31, (in thousands) 2024 2023 Operating lease cost $ 1,951 $ 1,953 Variable lease cost 530 597 Total lease cost $ 2,481 $ 2,550
Summary of Amounts Reported in Condensed Consolidated Balance Sheets and Weighted-average Lease Term and Discount rate Information	Amounts reported in the condensed consolidated balance sheets and the weighted-average lease term and discount rate information were as follows: (in thousands except weighted-average amounts) March 31, 2024 December 31, 2023 Assets Operating lease right-of-use assets $ 38,816 $ 40,048 Liabilities Operating lease liabilities, current $ 3,957 $ 3,830 Operating lease liabilities, non-current 30,782 31,830 Total lease liabilities $ 34,739 $ 35,660 Weighted-Average Lease Term and Discount Rate Weighted-average remaining lease term (years) 6.5 6.7 Weighted-average discount rate 8.2 % 8.2 %
Summary of Other Lease Activity	The following table represents other lease activity: Three Months Ended March 31, (in thousands) 2024 2023 Other Information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 1,639 $ 1,544 Right-of-use assets obtained in exchange for lease obligations $ — $ 270

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, (in thousands, except share and per share amounts) 2024 2023 Numerator: Net loss attributable to common stockholders $ ( 30,804 ) $ ( 28,433 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 68,030,966 66,265,703 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.45 ) $ ( 0.43 )
Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The Company’s potentially dilutive securities were stock options, unvested restricted stock and restricted stock units. Based on the amounts outstanding as of March 31, 2024 and 2023, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: As of March 31, 2024 2023 Options to purchase common stock 9,617,839 7,872,497 Unvested restricted stock 7,725 56,162 Restricted stock units 1,870,070 1,792,185

Nature of the Business - Additi

Nature of the Business - Additional Information (Details)	3 Months Ended
	Mar. 31, 2024
Nature Of Business [Line Items]
Incorporation date	Dec. 30, 2015

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 62,602	$ 105,892
Gross Unrealized Holding Gains		18
Gross Unrealized Holding losses	(87)	(95)
Fair Value	62,515	105,815
Maturing in One Year or Less | U.S. Treasury Bill
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	8,924	8,806
Gross Unrealized Holding Gains		6
Gross Unrealized Holding losses	(1)
Fair Value	8,923	8,812
Maturing in One Year or Less | U.S. Treasuries
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	43,758	97,086
Gross Unrealized Holding Gains		12
Gross Unrealized Holding losses	(35)	(95)
Fair Value	43,723	$ 97,003
Maturing after One Year through Five Years | U.S. Treasuries
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	9,920
Gross Unrealized Holding losses	(51)
Fair Value	$ 9,869

Marketable Securities - Summa_2

Marketable Securities - Summary of Fair Value and Gross Unrealized Losses of Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]
Less than twelve months Fair value	$ 35,685
Less than twelve months Unrealized loss	(54)
Greater than twelve months Fair value	26,830	$ 53,447
Greater than twelve months Unrealized loss	(33)	(95)
Total Fair value	62,515	53,447
Total Unrealized loss	(87)	(95)
U.S. Treasury Bill
Debt Securities, Available-for-Sale [Line Items]
Less than twelve months Fair value	8,923
Less than twelve months Unrealized loss	(1)
Total Fair value	8,923
Total Unrealized loss	(1)
U.S. Treasuries
Debt Securities, Available-for-Sale [Line Items]
Less than twelve months Fair value	26,762
Less than twelve months Unrealized loss	(53)
Greater than twelve months Fair value	26,830	53,447
Greater than twelve months Unrealized loss	(33)	(95)
Total Fair value	53,592	53,447
Total Unrealized loss	$ (86)	$ (95)

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Credit losses related to marketable securities	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	$ 109,796	$ 139,392
Marketable Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	62,515	105,815
Marketable Securities | U.S. Treasury Bill
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	8,923	8,812
Marketable Securities | U.S. Treasuries
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	53,592	97,003
Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	44,868	31,164
Restricted Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	2,413	2,413
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	56,204	42,389
Level 1 | Marketable Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	8,923	8,812
Level 1 | Marketable Securities | U.S. Treasury Bill
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	8,923	8,812
Level 1 | Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	44,868	31,164
Level 1 | Restricted Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	2,413	2,413
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	53,592	97,003
Level 2 | Marketable Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	53,592	97,003
Level 2 | Marketable Securities | U.S. Treasuries
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	$ 53,592	$ 97,003

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	3 Months Ended
	Mar. 31, 2024 USD ($)
Fair Value Disclosures [Abstract]
Fair value assets, level 1 to level 2 transfers amount	$ 0
Fair value assets, level 2 to level 1 transfers amount	0
Fair value assets, transfers into level 3	0
Fair value assets, transfers out of level 3	$ 0

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Total	$ 18,199	$ 18,141
Less: Accumulated depreciation	(9,034)	(8,091)
Property and equipment, net	9,165	10,050
Laboratory Equipment
Property Plant And Equipment [Line Items]
Total	10,090	10,028
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Total	7,028	6,936
Computer Equipment
Property Plant And Equipment [Line Items]
Total	432	432
Furniture, Fixtures and Other
Property Plant And Equipment [Line Items]
Total	620	599
Construction in Progress
Property Plant And Equipment [Line Items]
Total	$ 29	$ 146

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 943	$ 837

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Employee-related expenses	$ 1,908	$ 5,962
Professional fees	1,192	1,245
Clinical expenses	1,748	1,495
Manufacturing expenses	1,138	842
Research and development expenses	592	1,059
Other	219	274
Total accrued liabilities	$ 6,797	$ 10,877

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	1,449,975	1,543,219
Weighted-average grant-date fair value of stock options granted	$ 1.84	$ 3.98
Unrecognized compensation expense related to stock options	$ 14
Unrecognized share based compensation expense, recognition period	2 years 7 months 6 days
Number unvested options	7,725
Weighted average exercise price of options exercised and unvested	$ 4.9
Proceeds from unvested options exercises	$ 0.1
Employee Stock Purchase Plan 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued	0	0
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting rights description	vest over 48 months with 25% vesting after one year followed by ratable monthly vesting over the remaining three years
Vesting period	48 months
Contractual term	10 years
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units granted	1,070,025	645,360
Weighted average grant date fair value of restricted stock, granted	$ 2.41	$ 5.55
Unrecognized compensation expense related to related to restricted stock units	$ 6
Unrecognized share based compensation expense, recognition period	2 years 2 months 12 days
Common Stock | Employee Stock Purchase Plan 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future issuance	1,968,620
Tranche One | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	1 year
Vesting percentage	25%
Tranche Two | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
2023 Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future issuance	3,127,811
2021 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future issuance	1,845,382

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Weighted-Average Assumptions Used Principally in Determining Fair Value of Options Granted (Details) - Stock Options	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years	6 years
Expected volatility	90.80%	82.10%
Risk-free interest rate	4%	3.80%
Dividend yield	0%	0%

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 3,081	$ 4,068
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,405	2,354
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,676	$ 1,714

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions			3 Months Ended
	Apr. 29, 2022	Jan. 28, 2022	Mar. 31, 2024
Standby Letters of Credit
Lessee Lease Description [Line Items]
Increase in irrevocable line of credit facility			$ 2.4
First Lease Amendment
Lessee Lease Description [Line Items]
Operating lease commencement date		Jan. 28, 2022
Aggregate total fixed rent payments		$ 8.4
Second Lease Amendment
Lessee Lease Description [Line Items]
Operating lease commencement date	Apr. 29, 2022
Aggregate total fixed rent payments	$ 22.3
Cambridgepark Lease
Lessee Lease Description [Line Items]
Lessee, Operating Lease, Existence of Option to Extend [true false]			false

Leases - Summary of Lease Expen

Leases - Summary of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating lease cost	$ 1,951	$ 1,953
Variable lease cost	530	597
Total lease cost	$ 2,481	$ 2,550

Leases - Summary of Amounts Rep

Leases - Summary of Amounts Reported in Condensed Consolidated Balance Sheets and Weighted-average Lease Term and Discount rate Information (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Operating lease right-of-use assets	$ 38,816	$ 40,048
Liabilities
Operating lease liabilities, current	3,957	3,830
Operating lease liabilities, non-current	30,782	31,830
Total lease liabilities	$ 34,739	$ 35,660
Weighted Average Lease Term and Discount Rate
Weighted-average remaining lease term (years)	6 years 6 months	6 years 8 months 12 days
Weighted-average discount rate	8.20%	8.20%

Leases - Summary of Other Lease

Leases - Summary of Other Lease Activity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]
Operating cash flows for operating leases	$ 1,639	$ 1,544
Right-of-use assets obtained in exchange for lease obligations		$ 270

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net loss attributable to common stockholders	$ (30,804)	$ (28,433)
Denominator, basic
Weighted-average number of common shares outstanding, basic	68,030,966	66,265,703
Net loss per share attributable to common stockholders, basic	$ (0.45)	$ (0.43)
Denominator, diluted
Weighted-average number of common shares outstanding, diluted	68,030,966	66,265,703
Net loss per share attributable to common stockholders, diluted	$ (0.45)	$ (0.43)

Net Loss Per Share - Potential

Net Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share	9,617,839	7,872,497
Unvested Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share	7,725	56,162
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share	1,870,070	1,792,185